Lacidipine
Modify Date: 2025-08-21 12:46:50
Lacidipine structure
|
Common Name | Lacidipine | ||
|---|---|---|---|---|
| CAS Number | 103890-78-4 | Molecular Weight | 455.543 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 558.4±50.0 °C at 760 mmHg | |
| Molecular Formula | C26H33NO6 | Melting Point | 174-175°C | |
| MSDS | Chinese USA | Flash Point | 291.5±30.1 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of LacidipineLacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Target: Calcium ChannelLacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension. lacidipine protects HKCs against apoptosis induced by ATP depletion and recovery by regulating the caspase-3 pathway [1]. In biological membranes deriving from rat brain tissue, lacidipine showed an activity comparable to reference antioxidant compounds like vitamin E [2]. lacidipine has some important protective effects on liver of hypertensive irradiated albino rats [3]. |
| Name | diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate |
|---|---|
| Synonym | More Synonyms |
| Description | Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Target: Calcium ChannelLacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension. lacidipine protects HKCs against apoptosis induced by ATP depletion and recovery by regulating the caspase-3 pathway [1]. In biological membranes deriving from rat brain tissue, lacidipine showed an activity comparable to reference antioxidant compounds like vitamin E [2]. lacidipine has some important protective effects on liver of hypertensive irradiated albino rats [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 558.4±50.0 °C at 760 mmHg |
| Melting Point | 174-175°C |
| Molecular Formula | C26H33NO6 |
| Molecular Weight | 455.543 |
| Flash Point | 291.5±30.1 °C |
| Exact Mass | 455.230774 |
| PSA | 90.93000 |
| LogP | 5.49 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.540 |
| InChIKey | GKQPCPXONLDCMU-CCEZHUSRSA-N |
| SMILES | CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C |
| Storage condition | -20?C Freezer |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | C,Xi |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S26-S36/37/39-S45 |
| RIDADR | UN 3265 8/PG 2 |
| WGK Germany | 3 |
| Packaging Group | III |
| Hazard Class | 8 |
| HS Code | 2933399090 |
|
~41%
Lacidipine CAS#:103890-78-4 |
| Literature: Sajja, Eswaraiah; Vetukuri, Venkata Naga Kali Vara Prasada Raju; Ningam, Srinivas Reddy; Vedantham, Ravindra Patent: US2007/43088 A1, 2007 ; Location in patent: Page/Page column 6 ; |
|
~%
Lacidipine CAS#:103890-78-4 |
| Literature: US4801599 A1, ; |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Possible hepatoprotective effects of lacidipine in irradiated DOCA-salt hypertensive albino rats.
Pak. J. Biol. Sci. 16(21) , 1353-7, (2013) Calcium channel blockers are increasingly used for the treatment of hypertension. Hypertension is an important risk factor for liver damage and several other circulatory abnormalities. The aim of this... |
|
|
Effect of long-term antihypertensive treatment on white-coat hypertension.
Hypertension 64(6) , 1388-98, (2014) Limited evidence is available on the extent and frequency by which antihypertensive treatment lowers office blood pressure (BP) in white-coat hypertension (WCH). Data are even more scanty and discrepa... |
|
|
Ordered mesoporous silica material SBA-15: loading of new calcium channel blocker--lacidipine.
J. Microencapsul. 30(1) , 21-7, (2013) Mesoporous material SBA-15 of hexagonal structure was synthesised and its usefulness as a carrier for a poorly soluble drug--lacidipine (LA)--was tested. The source of silica was tetraethyl orthosilic... |
| Caldine |
| Diethyl 2,6-dimethyl-4-(2-{(1E)-3-[(2-methyl-2-propanyl)oxy]-3-oxo-1-propen-1-yl}phenyl)-1,4-dihydro-3,5-pyridinedicarboxylate |
| 4-[o-[(E)-2-Carboxyvinyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid 4-tert-Butyl Diethyl Ester |
| Diethyl 4-{2-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Diethyl (E)-4-[2-[2-(tert-butoxycarbonyl)vinyl]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Lacipil |
| (E)-4-[2-[3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester |
| MFCD00865936 |
| Lacirex |
| 3,5-Pyridinedicarboxylic acid, 4-[2-[(1E)-3-(1,1-dimethylethoxy)-3-oxo-1-propen-1-yl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester |
| Lacidipine |
| Motens |